The assessment of cardiac function, NT-proBNP levels, hepatic and renal function, electrolyte balance, and MLHFQ scores in heart failure patients treated with Vericiguat combined with the “new quadruple” regimen for 1 month demonstrated significant improvements in LAD, LVESD, LVEDD, LVEF, NT-proBNP levels, and MLHFQ scores compared to pre-treatment values (P < 0.01). Here, NPPB is linked to heart failure.